Cooperative Agreement UG3CA309249
Award Date 9/3/26
Completion Date 8/31/28
Dollars Obligated $671K
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
New York, NY 10016, USA
Similar Awards
- The National Cancer Institute awarded the University of Pittsburgh $396,799 on April 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop biomarkers and computational models for predicting adenoma recurrence in patients with advanced adenomas. The project funds evaluation of colorectal lesions using two novel approaches: assessment of aberrant alterations in chromatin structure at nanoscale sensitivity, and spatial analysis of tissue samples. The research...
- The National Cancer Institute awarded The University of Chicago $692,063 on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to advance early colorectal cancer diagnosis and risk stratification using DNA methylation markers. The funded work develops blood-based biomarkers to detect colorectal cancer and advanced adenomas through cell-free DNA analysis, addressing the gap in sensitivity of existing tools such as MSEPT9, Cologuard, and Shield. The research...
- The National Cancer Institute awarded the University of Southern California $699,303 on August 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to identify pre-diagnostic epigenetic biomarkers of colorectal cancer risk and understand epigenetic mechanisms of lifestyle and genetic CRC risk factors across multiple U.S. populations. The research will conduct a nested case-control study of 1,500 colorectal cancer cases and 1,500 matched controls drawn from the...
- The National Cancer Institute awarded Pennsylvania State University (operating as Penn State Milton S. Hershey Medical Center) $639,477 on July 15, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a randomized controlled trial evaluating the impact of self-sampling tools on cancer screening completion and repeat screening among underscreened patients. The recipient will randomize 742 patients eligible but out-of-date with colorectal cancer screening and 250...
- The National Cancer Institute awarded Weill Medical College of Cornell University $702,461 on June 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to evaluate a novel educational intervention designed to improve timely colposcopy follow-up and treatment among high-risk populations with abnormal cervical cancer screening results. The funded project conducts a hybrid implementation-effectiveness trial testing the COLPO (Clear Communication, Optimize Follow Up,...
- The National Cancer Institute awarded Cold Spring Harbor Laboratory $704,182 under the Cancer Biology Research program (CFDA 93.396) on June 16, 2026, to dissect non-mutational mechanisms driving benign-to-malignant transition in colorectal cancer. The project uses a novel mouse model that stepwise acquires mutations mirroring human colorectal cancer progression—starting with APC knockout to initiate benign polyps, then inducing KRAS G12V and TP53 loss in rare cells within established polyps...
- The National Cancer Institute awarded a cooperative agreement totaling $738,675 to Beckman Research Institute of the City of Hope on March 16, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop an exosome-based liquid biopsy assay for non-invasive early detection of colorectal adenomas and cancers. The project addresses the limitation that current fecal immunochemical testing (FIT) shows declining sensitivity for early-stage colorectal cancer and advanced...
- The National Cancer Institute awarded New York University $703,227 on June 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop an ultra-rapid droplet digital PCR method for real-time molecular profiling of cancer-driving mutations during surgical resection. The funded work aims to engineer a microfluidic device that automates ultra-rapid DNA extraction and PCR thermal cycling to profile tissue samples in minutes rather than hours, enabling surgeons to...
- The National Cancer Institute awarded Louisiana State University Health Sciences Center New Orleans $380,554 on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a pilot adaptive trial optimizing patient navigation interventions to promote fecal immunochemical test (FIT) colorectal cancer screening among rural residents. The study employs a two-stage sequential multiple assignment randomized trial (SMART) design. Stage 1 evaluates chatbot-based...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded New York University $701,574 on August 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate APOBEC3-induced mutagenesis in cancer development and therapy resistance. The funded research develops experimental and bioinformatics methods to track de novo generation of specific mutational signatures (SBS2 and SBS13) induced by individual...